Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
NEW HAVEN, Conn., June 28, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is presenting expanded data from two randomized, pivotal Phase 3 clinical trials of rimegepant, Biohaven's small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, on...
- Source: PR Newswire
- Read article...
More Headlines
- Easy Come, Easy Go: How Solargiga Energy Holdings (HKG:757) Shareholders Got Unlucky And Saw 73% Of Their Cash Evaporate
- What Kind Of Shareholder Appears On The Otto Energy Limited's (ASX:OEL) Shareholder Register?
- This is why self-driving cars suck at making unprotected left turns
- Oil prices stabilize after sharp falls earlier in week
- Is Keppel DC REIT (SGX:AJBU) An Attractive Dividend Stock?
- What Kind Of Share Price Volatility Should You Expect For Royale Furniture Holdings Limited (HKG:1198)?
- Middle East Crudes Seen Falling Off Quality Cliff on Ship Rules
- Disney's Hulu Strategy Is Emerging
- How Many Myanmar Metals Limited (ASX:MYL) Shares Did Insiders Buy, In The Last Year?
- If You Had Bought UMP Healthcare Holdings (HKG:722) Stock A Year Ago, You'd Be Sitting On A 14% Loss, Today
- US
- up
- year
- market
- billion
- government
- China
- 2014
- growth
- oil
- CHINESE
- economic
- sales
- data
- prices
- Energy
- economy
- down
- investment
- shares
- Global
- President
- gas
- industry
- central
- markets
- Power
- deal
- European
- quarter
- Japan
- foreign
- public
- Trading
- top
- Stocks
- sector
- Capital
- banks
- Tax
- development
- media
- executive
- rate
- Dollar
- LONDON
- Apple
- technology
- WASHINGTON
- profit
- interest
- revenue
US Stocks
- Garmin Earnings: 3 Takeaways
- CoStar Group, Inc. Bookings Soar 47%
- How General Motors Is Revamping Its Slowest-Selling Crossover SUV
- Stellar's 3 Most Intriguing Blockchain Partnerships
- George Soros Just Bought These 2 Biotech Stocks. Should You?
- Tax Reform Masks Earnings Declines at Graham Holdings
- Why Is No One Talking About Buckeye Partners, L.P. Stock?
- Leucadia Posts a Strong Finish to 2017
- Dorman Sees a Stronger 2018 Ahead
- Appian (APPN) Q4 2017 Earnings Conference Call Transcript
- Fitbit Makes an Acquisition That Might Finally Matter
- Wider Losses Worry NxStage Medical Shareholders
- 3 Things MercadoLibre's Management Wants You to Know
- 4 Things ManTech Wants Investors To Know
- What to Watch When EOG Resource Inc Reports Q4 Results
- Will J.C. Penney Benefit From Upheaval at Toys "R" Us?
- Why Is the NEO Cryptocurrency Soaring Today?
- A Foolish Take: Teens Will Keep Leaving Facebook
- A Foolish Take: Warren Buffett Has Crushed the Market for More Than Half a Century
- Here's Why MiMedx Group Inc. Is Crashing Again